

ParagraphFour.com  
Inter Partes Review List  
(IPR's 2023-- filed 10/1/2022 to 9/30/2023)

2023-00016 10/14/2022 -- 7,014,876 Trulance®(plecanatide) Tablets  
2023-00049 10/14/2022 -- 7,713,947 Mavenclad®(cladribine) Tablets  
2023-00050 10/14/2022 -- 8,377,903 Mavenclad®(cladribine) Tablets  
2023-00052 10/14/2022 -- 11,110,087 Venclexta®(venetoclax) Tablets  
2023-00442 1/6/2023 -- 10,130,681 Eylea®(aflibercept) Injection  
2023-00462 1/17/2023 -- 10,464,992 Eylea®(aflibercept) Injection  
2023-00480 1/23/2023 -- 7,713,947 Mavenclad®(cladribine) Tablets  
2023-00481 1/23/2023 -- 8,377,903 Mavenclad®(cladribine) Tablets  
2023-00478 2/3/2023 -- 10,272,083 Calquence®(acalabrutinib) Capsules  
2023-00482 2/10/2023 -- 10,849,919 Mavenclad®(cladribine) Tablets  
2023-00512 2/10/2023 -- 8,846,628 Onureg®(azacitidine) Tablets  
2023-00722 3/16/2023 -- 8,536,122 Ozempic®(semaglutide) Injection  
2023-00723 3/16/2023 -- 8,129,343 Ozempic®(semaglutide) Injection  
2023-00724 3/16/2023 -- 10,335,462 Ozempic®(semaglutide) Injection  
2023-01114 6/21/2023 -- 11,311,482 Arazlo®(tazarotene) Lotion